Appendix Table C6. Attributes of studies that address Key Question 1

| ID | HC | Enroll  Start | Enroll End | Design | Study  Setting | Treatment Setting | Institution  Setting(s) | Stage(s) | Staging Criteria | COI | Funding |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Andratschke, 2011, #132 | Y | 12/00 | 03/10 | RET | SI | NR | TH | I | AJCC 2002 | N | G |
| Baumann, 2006, #271 | N (24%) | XX/96 | XX/03 | RET | M | NR | NR | I | NR | NR | NR |
| Baumann, 2009, #270 | N (33%) | 08/03 | 09/05 | PRO | M | NR | NR | I | NR | NR | OH |
| Bogart, 2009, #382 | Y | 12/00 | 07/05 | PRO | NR | NR | NR | I | NR | Y | MA |
| Bollineni-2012, #4548 | N (70%) | 11/06 | 02/10 | RET | SI | NR | TH | I | AJCC 2002 | N | NR |
| Bradley,2003, #445 | Y | XX/91 | XX/01 | PRO | NR | NR | NR | I | AJCC 2002 | NR | NR |
| Burdick, 2010, #521 | N (32%) | 10/03 | 08/07 | RET | SI | NR | TH | I | AJCC 2002 | N | NR |
| Bush, 2004, #535 | Yes | NR | NR | PRO | SI | NR | TH | I | NR | NR | S |
| Campeau, 2009, #565 | Yes | 01/00 | 12/05 | RET | SI | NR | NR | I | Union Internationale Contre le Cancer | NR | NR |
| Coon, 2008, #803 | N (39%) | 01/05 | 01/07 | RET | SI | NR | TH | I | AJCC 2002 | NR | NR |
| Dunlap, 2010, #1032 | Yes | 03/05 | 01/08 | RET | SI | NR | TH | I | AJCC 2002 | NR | NR |
| Fritz, 2008, #1238 | Yes | NR | NR | RET | SI | NR | NR | I | NR | N | NR |
| Graham, 2006, #1403 | Yes | 01/95 | 12/02 | RET | M | NR | TH | I | NR | NR | NR |
| Iwata, 2010, #1747 | Yes | 04/03 | 04/07 | PRO | SI | NR | TH | I | IUAC 2002 | N | G |
| Jimenez, 2010, #1842 | Yes | 09/05 | 04/07 | RET | SI | NR | TH | I | NR | N | NR |
| Kopek, 2009, #2040 | Yes | 01/00 | 12/07 | PRO | SI | NR | TH | I | IUAC 1997 | NR | MA,S,G |
| Mirri, 2009, #2576 | N (27%) | 06/03 | 03/07 | PRO | SI | NR | TH | I | NR | NR | NR |
| Nakayama, 2010, #2684 | N (12%) | 11/01 | 07/08 | RET | M | NR | TH | I | IUAC2002 | NR | NR |
| Narayan, 2004, #2686 | Yes | NR | NR | PRO | M | NR | TH | I | NR | NR | G |
| Nyman, 2006, #2750 | N (20%) | 09/98 | 03/03 | RET | SI | NR | TH | I | NR | NR | NR |
| Olsen, 2011, #2792 | N (15%) | 06/04 | 06/09 | PRO | SI | NR | TH | I | AJCC 2009 | N | NR |
| Palma, 2011, #2843 | N (68%) | 01/03 | 03/10 | PRO | SI | NR | TH | I | NR | Y | NR |
| Pennathur, 2007, #2896 | Yes | 01/02 | 12/05 | RET | SI | NR | TH | I | NR | Y | MA,G |
| Pennathur, 2009, #2898 | N  (5%) | 01/02 | 12/05 | RET | SI | NR | TH | I | NR | NR | NR |
| Ricardi, 2010, #3098 | N (36%) | 05/03 | 08/07 | PRO | SI | NR | TH | I | NR | N | NR |
| Scorsetti, 2007, #3362 | N  (5%) | 01/04 | 01/06 | NR | M | NR | TH | I | NR | NR | NR |
| Shibamoto, 2012, #4269 | Y | 05/04 | 11/08 | PRO | M | NR | TH | I | IUAC2002 | N | NR |
| Song, 2009, #3549 | Yes | 06/99 | 05/06 | RET | SI | NR | TH | I | AJCC 2002 | N | G |
| Stephans, 2009, #3614 | N (29%) | 02/04 | 08/07 | RET | SI | NR | TH | I | AJCC 2002 | N | NR |
| Taremi, 2012, #3732 | N (25%) | 12/04 | 10/08 | PRO | SI | NR | TH | I | NR | N | MA,S,G |
| Takeda-2009, #3700 | N(18%) | 12/01 | 05/07 | RET | M | NR | TH | I | NR | N | NR |
| Turzer, 2011, #3842 | N (26%) | 09/08 | 04/10 | RET | SI | NR | TH | I | NR | NR | NR |
| Vahdat, 2010, #3864 | Yes | 01/05 | 01/08 | PRO | SI | NR | TH | I | NR | Y | NR |
| van der Voort van Zyp, 2009, #3885 | N (49%) | 08/05 | 10/07 | NR | SI | NR | TH | I | NR | N | NR |
| Videtic, 2010, #3958 | N (29%) | 10/03 | 11/06 | RET | SI | NR | TH | I | AJCC 2002 | N | NR |